Pelvic vein incompetence: clinical perspectives

David M Riding¹
Vivak Hansrani²
Charles McCollum¹

¹Academic Surgery Unit, University of Manchester, ²Department of Vascular Surgery, University Hospital of South Manchester, Manchester, UK

Abstract: Chronic pelvic pain (CPP) affects 24% of premenopausal women, accounts for 20%–30% of UK gynecology outpatient appointments, and has an annual pan-European economic cost of €3.8 billion. Despite extensive investigation, often including laparoscopy, up to 55% of women do not receive a diagnosis and endure persistent symptoms. In these patients, clinical management focuses on symptom control rather than treatment. It is possible that pelvic vein incompetence (PVI) is a cause of CPP, although the quality of studies investigating an association is generally low. PVI may develop during and after pregnancy, as uterine blood flow increases significantly, pushing venous valve leaflets apart, and enabling retrograde venous flow. Analogies with varicose veins of the lower limb are helpful, and symptoms are similar. Women with symptomatic PVI report a dull pelvic ache that is worse on standing and sitting and persists throughout the day. It can be relieved by lying down. Early treatments for PVI included laparoscopic ligation; however, since the advent of endovascular occlusive techniques, treatments have lower risk and lower cost, and can be undertaken without sedation or anesthetic. However, there have been no high-quality randomized controlled trials of interventions and, therefore, the evidence is limited to single-center case series.

Keywords: chronic pelvic pain, pelvic vein incompetence, women’s health

Introduction
Epidemiology of chronic pelvic pain
The Royal College of Obstetricians and Gynaecologists define chronic pelvic pain (CPP) as lower abdominal or pelvic pain that persists intermittently or continuously for greater than 6 months.¹ It should neither be associated with the menstrual cycle, nor should it occur solely with intercourse or pregnancy.¹ The term “chronic pelvic pain” does not represent a disease, but is a specific symptom, experienced by women and occurring secondary to a variety of pathologies. Clearly, men are able to experience lower abdominal or pelvic pain too, but the term has been accepted as pertaining solely to women.

A significant health problem, CPP affects thousands of women. Zondervan et al investigated a UK primary care database containing the medical records of 284,162 women aged 12–70, and found an incidence of 38/1,000 patients per year.² Equivalent figures for back pain (41/1,000), migraine (21/1,000), and asthma (37/1,000) provide useful comparison.² Latthe et al explored the global epidemiology of CPP in a well-designed and comprehensive systematic review of 459,972 participants, and found that, where high-quality data was available, there was a high prevalence of CPP (24%).³ The prevalence among women who did not seek medical attention but who have CPP
would not have been included in these analyses; therefore, the actual prevalence may be greater.

In addition to physical effects, CPP places a significant economic burden on individuals (where it may impede work capability) and on health budgets (where long-term management may be costly). CPP is associated with 20% of all gynecology outpatient appointments,\(^4\) costs US$881.5 million per annum in outpatient care costs in the US,\(^4\) with a total economic cost of US$2 billion per annum,\(^6\) and £158 million in the UK.\(^7\) Extrapolating those costs to the European population confers a cost of €3.8 billion per annum. Accordingly, there is a need to develop robust treatments and management strategies for women with CPP to ensure personal and societal costs can be minimized. Pelvic vein incompetence (PVI) may be a significant cause of CPP; this review considers the investigation and management of PVI in women with CPP.

**Literature review methods**
The MEDLINE, CINAHL, EMBASE and Cochrane Library databases were interrogated, using the following search terms: “pelvic congestion syndrome”, “pelvic venous incompetence”, “ovarian vein incompetence”, “iliac vein incompetence”, “pelvic varices” and “chronic pelvic pain”.

**Terminology**
The term “pelvic congestion syndrome” is often used as an umbrella term when CPP and PVI are found in the same patient. However, there is no published and accepted definition of which symptoms are characteristic to the syndrome. As we both PVI and CPP can be defined, but not “pelvic congestion syndrome”, we consider this alleged syndrome should, for now, not be a recognized entity.

**Pathophysiology of PVI**
The pathophysiology of PVI as a cause of CPP is best understood using the analogy of saphenous vein incompetence and chronic venous insufficiency of the lower limb. Here, venous valves fail and, therefore, retrograde flow down the saphenous vein is enabled. The pressure within the vein increases, and causes the venous diameter to increase, further separating the leaflets of the valves and increasing the capacitance of the system. Over time, the veins become tortuous and prominent, and chronic venous hypertension develops. This confers a “low flow” state on the capillary beds, which causes leukocyte trapping and an inflammatory response. The patient experiences aching and pain in the distribution of the affected vein, which is similar to the type of pain experienced by women with symptomatic PVI.\(^8\) In addition, symptoms are reported to diminish as the patient lies supine, emptying the pelvic veins and reducing their diameter.

No clear consensus has emerged to identify the underlying cause of the initial valve failure that enables the “vicious circle” of retrograde flow and diameetric expansion of the vein, but it is possible that the circulatory demands of the gravid uterus lead to an expansion in venous diameter, preventing the valvular leaflets from meeting within the lumen. Using Doppler sonography, Palmer et al found that pregnancy is associated with arterial flow speed and volumes up to eight times higher than non-pregnant controls.\(^9\) Physiological first principles suggest that this must be associated with a correspondingly higher volume of venous return. Veins do not have the elastic recoil of arteries, and so, postpartum, the venous diameter may be wide enough that the valvular leaflets still fail to meet, despite the reduced demand. However, PVI has been observed in women who have never been pregnant, and is often found incidentally in asymptomatic patients.\(^10,11\) Attempts have been made to establish a link between female endocrine hormones,\(^12\) endothelial cytokines,\(^13\) and the development of PVI, but such studies have not been sufficiently robust to confidently define the underlying molecular pathophysiology. To date, there has been very little research into why women develop PVI, and none of the endocrine or physiological studies have been replicated.

If idiopathic PVI can be considered “primary” PVI, then “secondary” PVI can arise as a result of venous obstructive disorders such as deep venous thrombosis, May–Thurner syndrome (compression of the left common iliac vein by the overlying right common iliac artery), and the “Nutcracker” syndrome (compression of the left renal vein between the abdominal aorta and the superior mesenteric artery). These are well-understood conditions that are treated separately from “primary” PVI and, thus, will not be included in this review.

In summary, to explain the pathophysiology of PVI, there are logical assumptions made in reference to lower limb varicose veins and logical hypotheses that are based on established vascular physiological principles; however, no high-quality studies of the pathophysiology of PVI have been completed.

**PVI as a cause of CPP**
The potential for PVI to cause CPP is accepted by many practitioners; however, there have been no robust case–control studies to support this view, with most data arising from small, non-powered, non-matched cohorts or case series with heterogeneous outcome measures. Beard et al investigated 45
women with CPP who had negative findings on laparoscopy by undertaking transfundal pelvic venography. They found that women with CPP had significantly greater mean maximum pelvic venous diameter than controls (6.73 mm vs 3.25 mm, p<0.01). However, 18 women were excluded from the study due to low-quality venographic images, and the cases and controls were not satisfactorily matched for age or parity.

The same group proceeded to compare symptoms of women with PVI and CPP against women with CPP only. In this study, women with PVI were more likely to experience exacerbating postural factors such as walking, standing, lifting, and bending, and were also more likely to experience associated symptoms such as back pain, vaginal discharge and headache. Although suggestive of an association, these relatively small studies do not conclusively confirm it. Furthermore, it is important to note that their definition of PVI was based on venous diameter, the time taken for venous contrast to disperse, and the radiological appearance of the venogram. Doppler technology was not available to assess intravenous flow dynamics that could have confirmed reflux within the affected veins. Reliance on surrogate markers of venous incompetence may increase the risk of Type I or Type II errors.

Transvaginal Doppler ultrasound (TVDU) was used by Halligan et al to confirm diagnoses of PVI made during transfundal venographic imaging. This study found that TVDU failed to discriminate between women found to have PVI on venography, and those who did not. However, the study was based on the assumption that transfundal venography was a “gold standard” screening tool for PVI, and that Doppler imaging is sensitive in the supine position. In addition, there were statistically significant differences between endometrial depth and uterine volume between the cases and controls, which may have made TVDU more difficult to interpret. Accordingly, their conclusion that the TVDU-detected rate of PVI was no different between cases of CPP and controls may not be valid.

This study highlights the need for standardized diagnostic criteria for PVI – both for research purposes and clinical assessment. Indeed, Champaneria et al’s systematic review of PVI and its association with CPP concludes that meta-analyses of these and similar studies are precluded by the heterogeneity of their diagnostic methods, outcome measures, and statistical credibility. Many such studies used the arbitrary scoring system (or a variation thereof) designed by Beard et al as the basis for their study, but recent work has sought to define standardized criteria on the basis of measurable physiological data. Hansrani et al used transvaginal Doppler-detected reflux of >0.5 seconds to represent a positive diagnosis of PVI. This study from our group found that women with PVI were more likely than patients with varicose veins or healthy controls to experience pain throughout the month (70% vs 25% vs 18%, p<0.001), pelvic pain (95% vs 62% vs 65%, p<0.008), and dyspareunia (42% vs 18% vs 15%, p=0.007). These data suggest that women with PVI are more likely to experience pelvic pain.

Our group reported a characteristic symptom profile that distinguishes PVI from other causes of CPP. Symptoms are similar to symptoms of lower limb varicose veins, but are experience in the pelvis. The pain is described as “aching”, worsens throughout the day, is exacerbated by standing for prolonged periods, and is relieved by lying.

To date, there have been no authoritative epidemiological studies of PVI as a cause of CPP. Several retrospective and prospective case series have reported that 11.2%–28% of patients with CPP have demonstrable PVI on investigation. However, these non-comparative studies are relatively low quality, with heterogeneity among the cohorts, and with a variety of imaging techniques employed. Moreover, there is heterogeneity of outcome measures, ranging from retrograde flow in the ovarian vein to the presence of pelvic varices. Similarly, studies examining PVI in women with recurrent varicose veins of the lower limb have found prevalence rates of 20%–76%, in the absence of methodological consistency and without adequate control groups. There remains a need for a well-powered epidemiological study with age- and parity-matched case-control pairs using clearly defined diagnostic criteria.

### Imaging techniques

Diagnostic laparoscopy is mandatory in the investigation of CPP. However, it is important to note that most laparoscopies are conducted with the patient supine, with minimal “on table” cranio-caudal tilting. Accordingly, the congested pelvic veins may empty and become difficult to identify during the procedure. Moreover, laparoscopy requires a positive pressure to be created within the abdominal cavity, which may further impede pelvic venous filling. As such, there is a need for non-laparoscopic imaging techniques to diagnose PVI. The ideal modality would enable a dynamic assessment of flow rate and direction within the pelvic venous system, and should be a sensitive and specific means of identifying pelvic varices, while minimizing radiation and contrast exposure.

At present, catheter-directed fluoroscopnic venography is considered the “gold standard” modality, as it allows the radiologist the opportunity to empty and refill the venous
system using a tilting table, and to target individual veins (Figure 1A). As stated previously, the primary challenge for clinicians is to confidently diagnose PVI in the absence of any universally accepted radiological diagnostic criteria. Studies designed to test alternative imaging modalities do so using fluoroscopic or transfundal venography as the reference standard.

The theoretical advantage of Doppler ultrasound techniques is that they are able to assess the direction of venous flow and the venous diameter using a relatively noninvasive technique without the risk of radiation or contrast. As such, they are a useful screening tool for patients being considered for fluoroscopic venography and transvenous occlusion, which (in practice) take place during the same consultation.

Barros et al undertook TVDU in 249 patients and found PVI in 150, with venography confirming PVI in 156 patients. These data demonstrated that TVDU had a sensitivity of 96% (95% confidence interval [CI] 92%–99%) and a specificity of 100% (lower 95% CI 97%).23 This study is particularly useful as all patients found to have PVI on TVDU proceeded to have venography, enabling meaningful comparison. However, it should be noted that the investigators who assessed the venography were not blinded to the results of the TVDU and, therefore, the data are at risk of significant bias. Furthermore, there was no clear definition of what constituted PVI at the time of imaging.

Park et al also used combined transabdominal and transvaginal Doppler ultrasound to assess women with PVI and CPP against healthy controls, and found that mean left ovarian vein diameter was greater in the cases than in the controls (0.79±0.23 vs 0.49±0.15 cm, p<0.001).24 Retrograde flow was identified in 100% of cases and 25% of controls, and all patients had identifiable varices and variable Duplex waveforms during the Valsalva maneuver. This study confirms the potential for TVDU to act as a reliable screening tool for patients suspected to have transvenous occlusion. The authors did not adequately explain why fewer than half the patients went on to have reference standard venography; it should also be noted that the authors did not define whether the Valsalva maneuver was used during the venography.

Figure 1 Venogram of incompetent left ovarian vein, pre- (A) and post-embolization (B).

Notes: a: left ovarian vein; b: characteristic dilatation of incompetent vein; c: pelvic varices; d: embolization coils in situ.
Magnetic resonance venography (MRV) has also been studied as an imaging modality for PVI. In 1994, Gupta et al reported a case of CPP where MR had been ordered to exclude adenomyosis, but obvious pelvic varices were the primary finding. Nascimento et al took this further by reporting a retrospective cases series of 22 healthy women who were noted to have passive reflux from the left renal vein into the left ovarian vein. The study by Ascuiotto et al reported sensitivity and specificity, respectively, of 88% and 67% for identification of ovarian vein reflux, 100% and 38% for the internal iliac veins, and 91% and 42% for the pelvic venous plexus. Crucially, the radiologists reporting the subsequent venograms were blinded to the MRV result during reporting. Similarly, Yang et al blinded their radiology reviewers and found sensitivities of 66.7%–75%, and specificities of 100%, although the retrospective design means these data should be considered cautiously. 27 MRV is reported to have a high sensitivity to detect pelvic varices in several small case series of patients with CPP, or recurrent varicose veins of the lower limb, but there remains no authoritative study comparing MRV findings with TVDU to define the most effective screening tool for fluoroscopic venography.

**Treatment of PVI**

The limited, early research into the treatment of PVI focused on the use of medical interventions, rather than more invasive modalities. Dihydroergotamine, medroxyprogesterone, etonogestrel implant, flavonoid, and goserelin have all been investigated and suggested to have some benefit, although outcome measures were variable and the studies were methodologically weak case series with low numbers of participants and no controls. Farquhar reported a randomized controlled trial of medroxyprogesterone (MPA) alone, versus MPA plus psychotherapy, placebo, and placebo plus psychotherapy. Visual analog scale (VAS) pain scores were reduced by 50% in the MPA plus psychotherapy group only. The authors did not adequately power the study, and were not able to fully explain why psychotherapy was chosen as one of the treatment arms. In addition, there were significant demographic differences between the four groups, particularly in parity and in the duration of symptoms. To date, there have been no authoritative studies that have shown clear evidence of benefit from medical therapies. Laparoscopic surgical interventions were briefly “en vogue” before the advent of endovascular techniques in the early 21st century. Grubham described a feasible and safe technique in an extremely limited case series of two patients. Gargiulio reported a case series of 23 women with PVI and pelvic pain who underwent laparoscopic ligation who then had complete remission of pain and absence of pelvic varicosities during the 12-month follow-up period; but again, no controls were used, and participant numbers were relatively small. The evidence to support the use of endovascular interventions for PVI is dominated by a large number of observational studies, often describing single-institution experience with a variety of occlusive techniques. Again, there is heterogeneity of PVI diagnostic criteria and outcome measures among these methodologically weak studies. The only study at Oxford CEBM Level 2b was authored by Chung and Huh, who randomized 106 CPP patients with venography-confirmed PVI to receive embolization, hysterectomy plus bilateral oophorectomy, or hysterectomy plus unilateral oophorectomy. VAS pain scores were reduced at 12 months compared to the control groups. No attempt was made to blind either patients or researchers, and there were no untreated control groups. Again, power calculations were not undertaken. More positively, all patients underwent diagnostic laparoscopy to exclude other causes of CPP prior to randomization, echoing the “real world” experience of such patients.

There have been a significant number of relatively low-quality studies reporting retrospective or prospective case series’ data that cumulatively provide a basis for further investigation. Most report significantly improved patient outcomes following endovascular embolization (Table 1), but there is significant heterogeneity among the diagnostic criteria for PVI and CPP, the outcome measures used, the patient demographics, and the pre-trial clinical assessment received by patients. In particular, many participants had not been reviewed by a gynecologist prior to enrolment, which is contrary to the “real world” practice of most clinicians. Occlusion methods were also variable, with some studies using either metallic coils, sclerotherapy agents, or both (Figure 1B). There was a lack of consistency of imaging among studies, and an over reliance on VAS of pain as the primary outcome measure. From our group, Hansrani et al concluded a systematic review of transvenous occlusion of PVI for CPP by calling for the inclusion of validated quality-of-life and pain questionnaires alongside the VAS.

Furthermore, it is important to acknowledge the significant number of studies investigating embolization of pelvic veins to treat recurrent varicose veins of the lower limb. It is now well understood that pelvic venous collaterals contribute to the recurrence of thigh varicose veins after long saphenous vein treatments have been administered. However, in common with studies pertaining to PVI and CPP, the data quality is
<table>
<thead>
<tr>
<th>Author</th>
<th>Study type</th>
<th>Eligibility criteria, number of participants</th>
<th>Procedure</th>
<th>Pain outcome measure</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asciutto et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=35</td>
<td>Ovarian and/or internal iliac vein embolization</td>
<td>Pain scores at 1–3 years</td>
<td>Mean pain score reduced from 5.2±3.5 to 1.2±0.9 at 3 years</td>
</tr>
<tr>
<td>Capasso et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=19</td>
<td>Ovarian vein embolization</td>
<td>Pain score at 4 weeks</td>
<td>74% had improved pain score</td>
</tr>
<tr>
<td>Chung and Huh</td>
<td>Randomized controlled trial</td>
<td>Premenopausal women with idiopathic CPP n=106</td>
<td>Ovarian vein embolization (49.0%) versus hysterectomy and bilateral oophorectomy (25.5%) versus hysterectomy plus unilateral oophorectomy (25.5%)</td>
<td>Pain scores at 3, 6 and 12 months</td>
<td>Mean pain score reduced from 4.5±0.9 to 3.2±0.9 in embolization group</td>
</tr>
<tr>
<td>Laborda et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=24</td>
<td>Ovarian vein embolization</td>
<td>Symptom relief, mean follow-up 13 months</td>
<td>88.9% had near-total symptom relief</td>
</tr>
<tr>
<td>Gandini et al.</td>
<td>Prospective observational</td>
<td>Women with CPP plus PVI on imaging n=38</td>
<td>Ovarian vein embolization</td>
<td>Pain scores at 1 year</td>
<td>Mean pain score reduced from 7.9 to 2.2</td>
</tr>
<tr>
<td>d’Archambeau et al</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=130</td>
<td>Ovarian vein embolization</td>
<td>Pain scores at 1, 3, 6 and 12 months</td>
<td>Mean pain score reduced from 7.8±1.8 to 2.7±2.8</td>
</tr>
<tr>
<td>Cordts et al.</td>
<td>Case series</td>
<td>Women with clinical PVI/PVI on imaging n=9</td>
<td>Ovarian vein embolization</td>
<td>Pain scores at 1–3 years</td>
<td>Mean pain score reduced from 5.5 to 1.0 at 45 days</td>
</tr>
<tr>
<td>Creton et al.</td>
<td>Prospective observational</td>
<td>Pre-menopausal women with dyspareunia and or dysmenorrhea/PVI on imaging n=24</td>
<td>Ovarian and/or internal iliac vein embolization</td>
<td>Pain scores at 45 days, 1–3 years</td>
<td>Mean pain score reduced from 5.5 to 1.0 at 45 days</td>
</tr>
<tr>
<td>Gilling-Smith</td>
<td>Observational study</td>
<td>Women with clinical PVI/PVI on imaging and CPP, plus lower limb varicose veins n=13</td>
<td>Ovarian and internal iliac vein embolization</td>
<td>Clinical assessment at 4 years</td>
<td>Full or partial resolution of symptoms in 100% of patients</td>
</tr>
<tr>
<td>Kwon et al.</td>
<td>Retrospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=127</td>
<td>Ovarian vein embolization (100%) plus internal iliac sclerotherapy (85%)</td>
<td>Pain scores at 3, 6, and annually</td>
<td>Mean pain score reduced from 7.6±1.8 to 2.9±2.8 at 45 months</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=67</td>
<td>Ovarian vein embolization</td>
<td>Pain scores, mean follow-up 45 months</td>
<td>82% of patients reported reduction in pain symptoms</td>
</tr>
<tr>
<td>Leal Monedero et al</td>
<td>Prospective observational</td>
<td>Women with CPP and varicose veins n=179</td>
<td>Ovarian vein embolization</td>
<td>Pain scores, 5 year follow-up</td>
<td>Full or partial resolution of pain in 87.0% of patients</td>
</tr>
<tr>
<td>Laborda et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging and lower limb varicose veins n=239</td>
<td>Embolization of ovarian and/or internal iliac veins, plus varicose vein treatments</td>
<td>Pain scores at 3, 6, and annually</td>
<td>Mean pain score reduced from 7.6±1.8 to 2.9±2.8 at 45 months</td>
</tr>
<tr>
<td>Maleux et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging and CPP n=41</td>
<td>Ovarian vein embolization</td>
<td>Pain scores, mean follow-up 20 months</td>
<td>69% of patients reported some or total pain relief</td>
</tr>
<tr>
<td>Meneses et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging and CPP, and undergoing surgery for recurrent varicose veins n=10</td>
<td>Ovarian and/or internal iliac embolization</td>
<td>Pain scores at 3 months</td>
<td>Mean pain score reduced from 8.2 to 4.0 at 3 months</td>
</tr>
<tr>
<td>Pieri et al.</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=33</td>
<td>Ovarian vein sclerotherapy</td>
<td>Pain symptoms at 1 moth</td>
<td>Pain symptoms improved in 61% of patients</td>
</tr>
<tr>
<td>Richardson and Driver</td>
<td>Case series</td>
<td>Women with clinical PVI/PVI on imaging and CPP n=26</td>
<td>Ovarian vein embolization</td>
<td>Pain scores, mean follow-up 22 months</td>
<td>Mean pain score reduced from 6.6±1.9 to 4.0±2.8</td>
</tr>
<tr>
<td>Sculente et al.</td>
<td>Prospective observational</td>
<td>Women with discomfort/duplex evidence of PVI n=15</td>
<td>Sclerotherapy/phlebectomy of visible varices</td>
<td>Pain scores, mean follow-up 2–3 years</td>
<td>80% reported significant improvement in pain symptoms</td>
</tr>
</tbody>
</table>

(Continued)
poor, with most studies scoring Level 4 or 5 on the Oxford CEBM classification. This overview of the evidence emphasizes the poor quality of data that characterizes all aspects of PVI and its associated clinical presentations.

**Summary**

Chronic pelvic pain is a major health problem that affects the lives of millions of women. The available evidence suggests that the management of CPP can be complex, and that symptom profiles are inconsistent and multifaceted. Investigations can be extensive, but can still fail to lead to effective treatment, with many women continuing to experience chronic pain despite seeking medical care. PVI may be an under-investigated, under-researched cause of CPP in women.

The optimal investigation and treatment of PVI to alleviate CPP is beginning to emerge. There is a multitude of low-quality evidence in the literature to support the hypotheses that TVDU is a useful screening tool for patients who may benefit from transvenous occlusion, and to also support the use of that treatment itself. However, the significant methodological flaws contained within the majority of these studies cannot be ignored. Similarly weak studies are unlikely to add to our knowledge and understanding of PVI; therefore, researchers should concentrate on producing higher quality data using comparative methodologies. Our group is currently undertaking a robust case–control study to define the frequency of PVI in women with CPP and in healthy volunteers. Our parallel randomized controlled trial of venography and coil/foam occlusion for women with CPP and PVI is also in progress. We will recruit 100 patients to the study, and compare pain scores, quality-of-life scores, and health economic data in both arms of the study.

We are proud to have formed the Manchester Pelvic Vein Study Group from an experienced multidisciplinary team of academic surgeons, radiologists, gynecologists, nurses, health economists, women’s health experts, and patient representatives, and are excited to explore this important condition, which may affect millions of women.

**Acknowledgments**

DMR and CM are partially funded by a National Institute of Health Research, Research for Patient Benefit grant (grant number PB-PG-0214-33102). We are grateful to Miss Rae Larmour who reviewed the images used in this review.

**Author contributions**

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


---

**Table 1 (Continued)**

<table>
<thead>
<tr>
<th>Author</th>
<th>Study type</th>
<th>Eligibility criteria, number of participants</th>
<th>Procedure</th>
<th>Pain outcome measure</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tarazov et al</td>
<td>Observational</td>
<td>Women with clinical PVI/PVI on imaging n=6</td>
<td>Ovarian vein embolization</td>
<td>Pain scores, 1–4 years</td>
<td>100% had complete resolution of pain</td>
</tr>
<tr>
<td>Tropeano et al</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging and idiopathic CPP n=20</td>
<td>Ovarian vein sclerotherapy</td>
<td>Pain scores at 3, 6 and 12 months</td>
<td>Median pain score reduced from 8.0 to 3.0 at 12 months</td>
</tr>
<tr>
<td>van der Vleuten et al</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging and CPP n=21</td>
<td>Ovarian vein embolization</td>
<td>Pain symptoms at 2 months</td>
<td>61.9% reported moderate or obvious improvement at 2 months</td>
</tr>
<tr>
<td>Venbrux et al</td>
<td>Prospective observational</td>
<td>Women with clinical PVI/PVI on imaging n=56</td>
<td>Ovarian (in 100% of patients and internal iliac embolization (in 77%))</td>
<td>Pain scores at 3, 6, and 12 months</td>
<td>Mean pain score reduced from 7.8 at baseline to 2.7 at 12 months</td>
</tr>
</tbody>
</table>

Abbreviations: CPP, chronic pelvic pain; PVI, pelvic vein incompetence.


Vascular Health and Risk Management

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal


Dovepress

Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapies and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particular